Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 26

Results For "capital"

708 News Found

PMBJP has led to a total savings of Rs. 30,000 crore for citizens: Health Minister Nadda
Policy | March 03, 2025

PMBJP has led to a total savings of Rs. 30,000 crore for citizens: Health Minister Nadda

In financial year 2024-25, PMBJP has made sales of Rs. 1,760 crore (at MRP) till Feb 2025


Healthcare Triangle announces $15.2 million PIPE offering
News | March 01, 2025

Healthcare Triangle announces $15.2 million PIPE offering

The PIPE offering consists of 36,190,476 units


India’s CRDMO sector growth potential at $22 - $25 Billion by 2035: BCG-IPSO Report
News | February 26, 2025

India’s CRDMO sector growth potential at $22 - $25 Billion by 2035: BCG-IPSO Report

Eleven CRDMOs collaborate to form IPSO with the aim to elevate India’s position in the global pharmaceutical value-chain


Aster DM Healthcare to invest Rs. 850 crore in next 3 years in Kerala
News | February 22, 2025

Aster DM Healthcare to invest Rs. 850 crore in next 3 years in Kerala

Aster commits to increase bed capacity in the State via capacity expansion and greenfield projects


Nectar Life Care launches affordable anti-diabetic range of medicines
News | February 17, 2025

Nectar Life Care launches affordable anti-diabetic range of medicines

Offers affordable, high-quality solutions for diabetes care


Hikal Q3 FY25 consolidated revenue recorded at Rs. 448 Cr
News | February 06, 2025

Hikal Q3 FY25 consolidated revenue recorded at Rs. 448 Cr

The stable raw materials prices, focused cost improvement initiatives and intensified customer acquisitions helped the company to improve its margin profile


Nectar Lifesciences posts Q3 FY25 PAT at Rs. 7.84 Cr
News | February 03, 2025

Nectar Lifesciences posts Q3 FY25 PAT at Rs. 7.84 Cr

Revenue from Operations for Q3 FY25 was Rs. 454.33 crore,


Biocon’s S&P Global ESG Score improves to 69 for 2024
Sustainability | January 30, 2025

Biocon’s S&P Global ESG Score improves to 69 for 2024

Biocon’s subsidiary Biocon Biologics Limited, which also participated independently in the assessment for the first time, reported an S&P Global ESG Score of 53


Neuland Labs board approves Capex of Rs. 342 Cr
News | January 23, 2025

Neuland Labs board approves Capex of Rs. 342 Cr

The company plans to fund this Capex through debt and internal accruals and expects the project to be completed by FY27


Strides Pharma debuts with ESG rating of 76/100 in the S&P Global’s CSA 2024
Sustainability | January 23, 2025

Strides Pharma debuts with ESG rating of 76/100 in the S&P Global’s CSA 2024

Scored 85/100, 2.3x the industry average in Social and 73/100, 1.8x the industry average in Governance